Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Core Insights - VolitionRx Limited announced that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in sepsis and septic shock patients [1][2] Group 1: Study Findings - The study indicates that Nu.Q® NETs H3.1 shows significantly higher levels in septic shock patients compared to those with sepsis, establishing a clear dose-response relationship with acute kidney injury severity [2][3] - The research involved a secondary analysis of plasma samples from 971 patients with sepsis and septic shock, part of the SISPCT trial [3] Group 2: Clinical Implications - The findings suggest that Nu.Q® NETs H3.1 could enhance risk stratification and early intervention in critically ill patients, potentially improving patient outcomes [2][4] - The ability to predict a sepsis patient's clinical course early using Nu.Q® NETs could significantly improve sepsis management [4] Group 3: Company Developments - Volition is engaged in commercial discussions with major players in the diagnostic space, leveraging the study's findings to support ongoing licensing processes [5] - The company is focused on developing cost-effective blood tests for diagnosing and monitoring various diseases, including sepsis [7]